// App-Quantinova.ai

7095 : ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)Final results.

Researchers

Presenter

  • Bartomeu Massuti

Principal Investigators

  • Ramon Lecumberri

  • Guillermo M Lopez Vivanco

  • Alfonso Gurpide

  • Vicente Vicente

  • Rafael Rosell

  • Mayte Monreal

  • Eduardo Rocha

  • Albert Font

  • Enrique Gonzalez-Billalabeitia

  • Juan Luis Marti-Ciriquian

  • Jose Gomez-Codina

  • Manuel Domine

  • Isabel Bover

  • Dolores Isla

  • Antonio Galan

Medical Centers

  • Laboratorios Farmaceuticos Rovi SA, Madrid, Spain

  • Hospital La Fe, Valencia, Spain

  • Pangaea Biotech, USP Institut Universitari Dexeus, Barcelona, Spain

  • Albacete University Hospital, Albacete, Spain

  • Hospital Universitario Morales Meseguer, Murcia, Spain

  • Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain

  • Fundacion Jimenez Diaz, Madrid, Spain

  • Hematology and Medical Oncology Department, University Hospital Morales Meseguer, UMU, IMIB, Murcia, Spain

  • Catalan Institute of Oncology, Germans Trias, Barcelona, Spain

  • Hospital Cruces, Bilbao, Spain

  • GEICO and Son Llatzer University Hospital, Mallorca, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Carboplatin

  • Bemiparin

  • Etoposide

  • Etoposide phosphate

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved